JOJohn-Paul Ong

John-Paul Ong

*This is an algorithmically generated author record based on publicly available information.

John-Paul Ong has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CanProTarget: A Residue-Resolved Platform for Covalent Target Identification and Drug Discovery in Cancer

    by John-Paul Ong, Jessica Bell, Daniel Martins, Joshua Zhu, Tiago Rodrigues, Jean Bertoldo

    Dependency maps nominate transcription factors, RNA-binding proteins and scaffolds without conventional binding sites, while cysteine chemoproteomics has mapped tens of thousands of ligandable sites without reference to disease. Covalent campaigns therefore begin from what is tractable rather than from what a cancer requires. Whether a ligandable cysteine matters requires residue-level functional evidence, and no resource holds all three: combined at the gene level, function measured at one cysteine is credited to a ligand bound at another. We developed CanProTarget to establish where covalent chemistry can realistically begin, returning target–cysteine–ligand hypotheses rather than gene lists. Across twenty adult and pediatric cohorts, 63–75% of gene-level candidates lost support under residue matching. Roughly 80% of ligandable sites were untested rather than assayed non-functional, and the tiers keep them distinct. One untested site nominated IGF2BP3–Cys336–CL174 in neuroblastoma; CL174 engaged IGF2BP3, reduced its mRNA binding and, with depletion, identified BRD3 and H3-3A as IGF2BP3 targets.

  • Open Access

    Chemoproteomics in covalent cancer drug discovery

    by John-Paul Ong, Montana Dalziel, Dona Johns, Joshua Zhu, Jean Bertoldo